• Research Tree
  • Features
  • Pricing
  • Events
  • Reg.News
  • Short Interest
  • Explore Content
    • Explore

      • Providers
        • Providers

          • Free/Commissioned
          • High Net Worth Offering
          • Institutional Offering

          Free/Commissioned

          Research that is free to access for all investors. Companies commission these providers to write research about them.

          View Research

          What is our Main Bundle Offering?

          Brokers who write research on their corporate clients and make it available through our main bundle offering.

          View Research

          What is Institutional?

          Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.

          View Research
      • Regions
        • Regions

          • UK
          • Rest of EMEA
          • N America
          • APAC
          • LatAm
      • Exchanges
        • Exchanges

          • Aquis Apex
          • Australian Securities Exchange
          • Canadian Securities Exchange
          • Euronext Paris
          • London Stock Exchange (domestic)
          • SIX Swiss Exchange
      • Sectors
        • Sector Coverage

          • Building & Construction
          • Discretionary Personal Goods
          • Discretionary Retail
          • Energy
          • Health
          • Investment Trusts
          • Media
          • Resources
          • Technology
      • Small / Large Cap
        • Small / Large Cap

          • UK100
          • UK250
          • UK Smallcap
          • UK Other Main Markets
          • Other
  • Login
  • Sign Up
LIVE

Event in Progress:

Join Here ×

working
  • 10 Apr 2025

DRX: Record FY Financials; Lowering Estimates on Tariff Impacts


ADF Group Inc. (DRX:TSE) | 0 0 -1.9% | Mkt Cap: 38.0m


  • Atrium Research
    • Nicholas Cortellucci, CFA

    • 5 pages


 

What you need to know: • ADF reported Q4 & FY25 financials that were a slight miss to our estimates. • For Q4, revenue came in at $77.4M (-12% YoY) vs. our estimate of $80.0M and EBITDA came in at $19.2M (+24% YoY) vs. our estimate of $19.7M. • FY25 marked another stellar year for ADF, however, the tariff situation is impacting management’s ability to sign new contracts, who are now expecting a decline in revenue and margins in FY26. • ADF ended the quarter with $60.0M in cash and $189.6M in current assets. ADF Group (DRX:TSX, ADFJF:OTC) reported Q4 and FY25 financial results (ending January 31st) today before market open which slightly missed our estimates. In its outlook and on the conference call, management had a change of tone due to the new reality of tariffs affecting its ability to grow revenue. We are recalibrating our estimates to model a decline in FY26 and are lowering our target price to reflect the current state of the trade war. We are maintaining our BUY rating and decreasing our target price to $9.00/share on ADF Group. Key Highlights • Revenue for Q4 came in at $77.4M vs. our estimate of $80.0M and $88.4M last year, representing a 12% YoY decline. FY25 revenue was $339.6M vs. our estimate of $342.2M, equating to 3% YoY growth. • The order backlog came in at $293.1M (vs. $330.3M in Q3), extending through January 2027. This does not include the $120M of new contracts. • Gross margin for Q4 was 31% vs. our estimate of 29% and 24% in Q4 last year. FY25 gross margin came in at 32% compared to our estimate of 31%. • Q4 EBITDA came in at $19.2M (25% EBITDA margin, +24% YoY) compared to our estimate of $19.7M (25% margin) and $15.5M in Q4/24. FY25 EBITDA was $91.3M (27% margin, +63% YoY) vs. our estimate of $91.7M (27% margin). • EPS in Q4 of $0.30/share (or $9.1M in net income) compared to our estimate of $0.43/share (or $12.8M in net income). FY25 EPS was $1.84/share (+60% YoY) vs. our $2.03/share, representing a 34% ROE and 27% ROIC. • ADF posted $1.2M in capex in Q4 and $8.3M in FY25. This translated to $0.6M in FCFF in Q4 and $47.6M in FY25. • ADF purchased 721.3K shares during the quarter and 423.2K shares subsequent to the quarter (2% and 1% of its shares outstanding, respectively). • The Company ended the quarter with $60.0M in cash and $45.6M in debt.

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here
See all the research we have on this company.

DRX: Record FY Financials; Lowering Estimates on Tariff Impacts


ADF Group Inc. (DRX:TSE) | 0 0 -1.9% | Mkt Cap: 38.0m


  • Published: 10 Apr 2025
  • Author: Nicholas Cortellucci, CFA
  • Pages: 5
  • Atrium Research


What you need to know: • ADF reported Q4 & FY25 financials that were a slight miss to our estimates. • For Q4, revenue came in at $77.4M (-12% YoY) vs. our estimate of $80.0M and EBITDA came in at $19.2M (+24% YoY) vs. our estimate of $19.7M. • FY25 marked another stellar year for ADF, however, the tariff situation is impacting management’s ability to sign new contracts, who are now expecting a decline in revenue and margins in FY26. • ADF ended the quarter with $60.0M in cash and $189.6M in current assets. ADF Group (DRX:TSX, ADFJF:OTC) reported Q4 and FY25 financial results (ending January 31st) today before market open which slightly missed our estimates. In its outlook and on the conference call, management had a change of tone due to the new reality of tariffs affecting its ability to grow revenue. We are recalibrating our estimates to model a decline in FY26 and are lowering our target price to reflect the current state of the trade war. We are maintaining our BUY rating and decreasing our target price to $9.00/share on ADF Group. Key Highlights • Revenue for Q4 came in at $77.4M vs. our estimate of $80.0M and $88.4M last year, representing a 12% YoY decline. FY25 revenue was $339.6M vs. our estimate of $342.2M, equating to 3% YoY growth. • The order backlog came in at $293.1M (vs. $330.3M in Q3), extending through January 2027. This does not include the $120M of new contracts. • Gross margin for Q4 was 31% vs. our estimate of 29% and 24% in Q4 last year. FY25 gross margin came in at 32% compared to our estimate of 31%. • Q4 EBITDA came in at $19.2M (25% EBITDA margin, +24% YoY) compared to our estimate of $19.7M (25% margin) and $15.5M in Q4/24. FY25 EBITDA was $91.3M (27% margin, +63% YoY) vs. our estimate of $91.7M (27% margin). • EPS in Q4 of $0.30/share (or $9.1M in net income) compared to our estimate of $0.43/share (or $12.8M in net income). FY25 EPS was $1.84/share (+60% YoY) vs. our $2.03/share, representing a 34% ROE and 27% ROIC. • ADF posted $1.2M in capex in Q4 and $8.3M in FY25. This translated to $0.6M in FCFF in Q4 and $47.6M in FY25. • ADF purchased 721.3K shares during the quarter and 423.2K shares subsequent to the quarter (2% and 1% of its shares outstanding, respectively). • The Company ended the quarter with $60.0M in cash and $45.6M in debt.

More Content

More Content

Q1/25 Recap: All Our Research in One Place!

Companies: NIM SCZ DRX AUAU ARG OMG BQE DNG EDG KNR MOO NIM RIO SBIO LVG TOC TM SCZ CAPT GIGA APM FISH

Atrium Research

Small-Caps with Torque to Infrastructure Spending

Companies: DRX CEMX QTRH GRID

Atrium Research

DRX: Back at It Again; $120M in New Contracts Signed

Companies: ADF Group Inc.

Atrium Research

DRX: Value Stock Entering Multi-Year Growth Cycle

Companies: ADF Group Inc.

Atrium Research

Finding the Next Takeout in Canadian Small-Caps - Part Four

Companies: GSI KUT IFX QIS HAI DRX BQE GCL COV CTX FTG GSI IFX PNG MAL NPTH QIS GRID SYZ VLN COV ETOLF

Atrium Research
Research Tree
Useful Links
  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub
  • Stock Pick League
  • Chrome Extension
  • iOS and Android Apps
Account
  • Login
  • Join Now
  • Contact
  • Follow us on Linkedin
  • Follow us on X

© Research Tree 2025

  • Apple Store
  • Play Store
  • Terms of Service
  • Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top
  • Home
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest Tracker
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Exchanges
      • Aquis Apex
      • Australian Securities Exchange
      • Canadian Securities Exchange
      • Euronext Paris
      • London Stock Exchange (domestic)
      • SIX Swiss Exchange
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • ETFs
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Investment Trusts
      • Leisure, Tourism & Travel
      • Media
      • Open-ended Funds
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Utilities
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Acquisdata
      • Actinver
      • Actio Advisors
      • Asset TV
      • Atrium Research
      • Baden Hill
      • BlytheRay
      • BNP Paribas Exane - Sponsored Research
      • Bondcritic
      • Brand Communications
      • BRR Media
      • Calvine Partners
      • Capital Access Group
      • Capital Link
      • Capital Markets Brokers
      • Cavendish
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Doceo
      • Edison
      • Engage Investor
      • Equity Development
      • eResearch
      • First Equity
      • Five Minute Pitch TV
      • focusIR
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • goetzpartners securities Limited
      • Golden Section Capital
      • GreenSome Finance
      • GSBR Research
      • H2 Radnor
      • Hardman & Co
      • Holland Advisors
      • Hypothesis Research
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Longspur Clean Energy
      • Mello Events
      • Messari Research
      • Nippon Investment Bespoke Research UK
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Optimo Capital
      • Panmure Liberum
      • Paul Scott
      • Peel Hunt
      • PIWORLD / Progressive
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • Research Dynamics
      • Research Tree
      • Resolve Research
      • SEAL Advisors Ltd
      • ShareSoc
      • Shore Capital
      • Sidoti & Company
      • Small Cap Consumer Research LLC
      • StockBox
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Edge Group
      • The Life Sciences Division
      • Trinity Delta
      • Turner Pope Investments
      • UK Investor Group
      • ValueTrack
      • Vox Markets
      • VRS International S.A. - Valuation & Research Specialists (VRS)
      • VSA Capital
      • Winterflood Securities
      • Yaru Investments
      • Yellowstone Advisory
      • Zacks Small Cap Research
      • Zeus Capital
    • High Net Worth Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Align Research
      • Allenby Capital
      • AlphaValue
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane - Sponsored Research
      • Canaccord Genuity
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • First Berlin
      • First Equity
      • First Sentinel
      • Greenwood Capital Partners
      • Hannam & Partners
      • Hybridan
      • Kemeny Capital
      • Longspur Clean Energy
      • Louis Capital
      • Magnitogorsk Iron and steel works
      • Medley Global Advisors
      • Northland Capital Partners
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • QuotedData Professional
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • Tennyson Securities
      • The Life Sciences Division
      • Turner Pope Investments
      • VSA Capital
      • Whitman Howard
      • Yellowstone Advisory
      • Zeus Capital
    • Institutional Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Acquisdata
      • Allenby Capital
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • BNP Paribas Exane
      • Bondcritic
      • Canaccord Genuity
      • Capital Access Group
      • Capital Link
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • Edison
      • First Berlin
      • First Equity
      • First Sentinel
      • Five Minute Pitch TV
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • Golden Section Capital
      • Goodbody
      • Greenwood Capital Partners
      • Hannam & Partners
      • Holland Advisors
      • Hybridan
      • InterAxS Global
      • Investec Bank
      • Kepler | Trust Intelligence
      • Numis
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • Peel Hunt
      • QuotedData
      • QuotedData Professional
      • Research Dynamics
      • Research Tree
      • Shard Capital
      • Shore Capital
      • Sidoti & Company
      • Singer Capital Markets
      • Small Cap Consumer Research LLC
      • SP Angel
      • Stanford Capital Partners
      • Stifel
      • StockBox
      • Tamesis Partners
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Life Sciences Division
      • ValueTrack
      • Velocity Trade
      • VSA Capital
      • Winterflood Securities
      • Zacks Small Cap Research
      • Zeus Capital
  • Contact
  • Sign Up
  • Sign In